Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease.
RC3
biomarkers
controls
diagnosis
neurodegeneration
prognosis
tau
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
12 Dec 2021
12 Dec 2021
Historique:
received:
16
09
2021
revised:
07
12
2021
accepted:
10
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
(1) Background: Neurogranin is a post-synaptic protein expressed in the neurons of the hippocampus and cerebral cortex. It has been recently proposed as a promising biomarker of synaptic dysfunction, especially in Alzheimer's disease (AD). However, more efforts are needed before introducing it in clinical practice, including the definition of its reference interval (RI). The aim of the study was to establish the RI of cerebrospinal fluid (CSF) neurogranin levels in controls and individuals with non-neurodegenerative neurological diseases; (2) We included a total of 136 individuals that were sub-grouped as follows: AD patients (
Identifiants
pubmed: 34943576
pii: diagnostics11122339
doi: 10.3390/diagnostics11122339
pmc: PMC8700711
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Brain Sci. 2021 Feb 27;11(3):
pubmed: 33673569
Int J Mol Sci. 2020 Nov 06;21(21):
pubmed: 33172069
Aging (Albany NY). 2020 May 18;12(10):9365-9379
pubmed: 32421689
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Dement Geriatr Cogn Dis Extra. 2018 Aug 6;8(2):277-289
pubmed: 30186306
Lab Med. 2021 Mar 15;52(2):188-196
pubmed: 32926148
Alzheimers Res Ther. 2015 Dec 24;7:74
pubmed: 26698298
Clin Chim Acta. 2020 Nov;510:272-277
pubmed: 32710941
Biomark Med. 2012 Aug;6(4):419-30
pubmed: 22917144
Biochem Med (Zagreb). 2017 Oct 15;27(3):030709
pubmed: 29180917
EJIFCC. 2008 Oct 16;19(2):106-14
pubmed: 27683305
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Clin Chem Lab Med. 2016 Dec 1;54(12):1893-1900
pubmed: 27748267
Alzheimers Res Ther. 2020 Mar 2;12(1):21
pubmed: 32122400
Scand J Clin Lab Invest. 2020 Jul;80(4):313-317
pubmed: 32255379
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Ann Clin Lab Sci. 2017 Aug;47(4):508-510
pubmed: 28801380
Biomark Insights. 2020 Aug 21;15:1177271920950319
pubmed: 32913390
Alzheimers Dement (N Y). 2019 Dec 09;5:871-882
pubmed: 31853477
Dement Neuropsychol. 2020 Jul-Sep;14(3):237-242
pubmed: 32973977
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11232-7
pubmed: 11016969
Front Aging Neurosci. 2021 Apr 27;13:667899
pubmed: 33986657
Front Aging Neurosci. 2020 Oct 06;12:584743
pubmed: 33132903
J Neurosci Res. 1990 Aug;26(4):397-408
pubmed: 2231781
Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20
pubmed: 26783546
Eur J Neurol. 2021 Jun;28(6):1868-1875
pubmed: 33638255
Neuron. 2016 Jul 6;91(1):56-66
pubmed: 27292537
Cell Mol Life Sci. 2019 May;76(10):1833-1863
pubmed: 30770953
EMBO J. 2009 Oct 7;28(19):2859-60
pubmed: 19809472
Exp Mol Med. 2018 Mar 23;50(3):e461
pubmed: 29568074
EMBO Mol Med. 2016 Oct 4;8(10):1184-1196
pubmed: 27534871
JAMA Neurol. 2016 May 1;73(5):561-71
pubmed: 27018940
J Pers Med. 2020 Nov 11;10(4):
pubmed: 33187336
Neurobiol Aging. 2021 Dec;108:99-109
pubmed: 34551375
Brain. 2015 Nov;138(Pt 11):3373-85
pubmed: 26373605
Nat Rev Neurol. 2015 Nov;11(11):609
pubmed: 26416540
JAMA Neurol. 2015 Nov;72(11):1275-80
pubmed: 26366630
Acta Neuropathol. 2018 Sep;136(3):363-376
pubmed: 29700597
Biochem Med (Zagreb). 2019 Jun 15;29(2):020901
pubmed: 31223265
EMBO J. 2009 Oct 7;28(19):3027-39
pubmed: 19713936
Neurobiol Dis. 2017 Aug;104:73-84
pubmed: 28392472
Int J Mol Sci. 2020 Mar 14;21(6):
pubmed: 32183332